An ardent advocate of protecting some of the world’s poorest countries from Covid-19 has been selected to lead the Biden administration’s vaccine diplomacy in an effort to corral wealthier nations into distributing immunizations more evenly around the globe.
Gayle Smith, a former U.S. Agency for International Development administrator and chief executive of the ONE Campaign to eradicate poverty and preventable disease, will step into the role, a new post at the State Department.
Provisional data compiled by the World Health Organization (WHO) from 84 countries indicates that an estimated 1.4 million fewer people received care for tuberculosis (TB) in 2020 than in 2019 - a reduction of 21% from 2019.
In the group of 10 high-burden countries with the largest reported shortfalls compared with 2019, the overall shortfall was 28%. With many people with TB unable to access care, WHO estimates that half a million more people may have died from TB in 2020 alone. TB remains one of the world’s top infectious killers.
It was three months after rich countries began vaccinating health workers, but Kenyans like the nurse, Stella Githaiga, had been left behind: Employed in the country’s largest public hospital, she caught the coronavirus on an outreach trip to remote communities in February, she believes, sidelining her even as Kenya struggles with a vicious third surge of infections.
Ms. Githaiga and her colleagues are victims of one of the most galling inequities in a pandemic that has exposed so many: Across the global south, health workers are being sickened and killed by a virus from which doctors and nurses in many rich countries are now largely protected.
That is just the most visible cost of a rich-poor divide that has deepened in the second year of the pandemic. Of the vaccine doses given globally, roughly three-quarters have gone to only 10 countries. At least 30 countries have not yet injected a single person.
(Reuters) - Nearly a dozen countries resumed use of AstraZeneca’s COVID-19 shots on Friday as EU and British regulators said its benefits outweighed any risks. Reports of rare instances of blood clotting had temporarily halted inoculations.
